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Identity 
Other names: CDMT, CYLD1, CYLDI, EAC, 
FLJ20180, FLJ31664, FLJ78684, HSPC057, 
KIAA0849, MFT, MFT1, SBS, TEM, USPL2 
HGNC (Hugo): CYLD 
Location: 16q12.1 
Local order: ...NOD2, CYLD, SALL1 (Rev)... 
DNA/RNA 
Description 
21 exons (17 coding) with alternative splicing (see 
figure 1). Size of the exons: 74 (bp), 98, 79, 136, 626, 
302, 105, 8, 98, 116, 379, 165, 141, 122, 91, 66, 132, 
108, 118, 216, 5611. The whole gene extends over 





956 aa, approximately 110 kD. 
Member of the deubiquitinase family (USP (Ubiquitin 
Specific Protease)) (Reyes-Turcu et al., 2009) with 
preferential affinity for K63-linked polyubiquitin 




Cytoplasm (might bind to microtubules through its 
CAP-Gly domains). 
Function 
CYLD has been primarily identified as a negative 
regulator of NF-kappaB signaling, able to bind NEMO 
and TRAF2 and to deubiquitinate them (Brummelkamp 
et al., 2003; Kovalenko et al., 2003; Trompouki et al.,
2003). It is also a negative regulator of JNK and p38 
signaling pathways (Reiley et al., 2004) and IRF-3 
signaling pathways (Friedman et al., 2008; Zhang et al., 
2008). It participates in antimicrobial defense and 
inflammation by targeting ubiquitinated TRAF6 (Lim 
et al., 2007; Lim et al., 2008) and is required for the 
development and activation of immune cells (Reiley et 
al., 2006; Jin et al., 2007). 
 
Figure 1. CYLD gene. Coding exons are indicated in dark red. Asterisks indicate exons which are differentially spliced. One of the exon 
which is alternatively present (Reiley et al., 2004) encodes the binding site for TRAF2 and NEMO (Hövelmeyer et al., 2007). 
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Figure 2. Structural organisation of CYLD. Binding sites for TRAF2 and NEMO are indicated. CAP: CAP-Gly domain, P: 
phosphorylation site, C and H: subdomains of the catalytic domain containing the Cys and His active residues. 
 
CYLD may also affect cell proliferation/cell cycling by 
targeting Plk1 and HDAC6 (Stegmeier et al., 2007; 
Massoumi et al., 2009) and cell migration via 
microtubule assembly (Gao et al., 2008). It controls 
spermatogenesis by deubiquitinating RIP (Wright et al., 
2007) and osteoclastogenesis by deubiquitinating 
TAK1 (Jin et al., 2008). A role for CYLD in the 
hypoxia response has been reported (An et al., 2008). 
Its inactivation by human papilloma virus-derived E6
protein results in hypoxia-induced NF-kappaB 
activation. Finally, it has been shown to affect calcium 
channel function by deubiquitinating TRPA1 (Stokes et 
al., 2006). 
CYLD interacts with NEMO (Kovalenko et al., 2003; 
Trompouki et al., 2003), TRAF2 (Kovalenko et al., 
2003; Trompouki et al., 2003), p62 (Wooten et al., 
2008), Bcl-3 (Massoumi et al., 2006), TAK1 (Reiley t 
al., 2007), RIP (Wright et al., 2007), lck (Reiley t al., 
2006), HDAC6 (Wickström et al., 2010). 
Homology 
Catalytic box (with other members of the 
deubiquitinase family (USPs)) and CAP-Gly (with a 




Tumor suppressor (Bignell et al., 2000). 
See full recent listing in Blake and Toro, 2009. Most f 
the mutations (non sense, frameshit, splicing) would 
produce large deletions of the protein but, most likely, 
produce mRNA nonsense-mediated decay. Short 
truncations affect the catalytic box which extends to the 
carboxy-terminus of the protein and produce an 
inactive enzyme. Very few missense mutations have  
 
been reported. All of them affect the catalytic box. 
Somatic 
Loss of heterozygosity in developing tumors. 
Implicated in 
Familial cylindromatosis and multiple 
trichoepithelioma 
Note 
Familial cylindromatosis, also called turban tumor 
syndrome is a rare inherited cancer which is 
characterized by the formation of benign tumors, called 
cylindroma, in hairy parts of the body, mostly the scalp. 
Cylindroma are considered as originating from a 
transformation event specifically affecting the 
folliculo-sebaceous-apocrine unit that produces hair 
and its associated glands. Early observations 
established that affected patients are heterozygous at 
birth for the locus causing the disease, whereas the 
cylindroma they develop exhibit a loss of 
heterozygosity (LOH) demonstrating the involvment of 
a gene coding for a tumor suppressor. More recently, it 
has been shown that another genetic disease sharing 
similarities with familial cylindromatosis, multiple 
trichoepithelioma (MT), is also caused by CYLD 
mutations (For reviews, see Massoumi and Paus, 2007; 
Courtois, 2008; Amaro et al., 2009). 
Various cancers 
Note 
Loss of CYLD has been reported in solid tumors of the 
colon and liver (Hellerbrand et al., 2007), kidney 
(Ströbel et al., 2002), cervix (Hirai et al., 2004) and 
prostate (Kikuno et al., 2008). CYLD is also 
epigenetically silenced in some non-small-cell lung 
cancers (NSCLC) (Zhong et al., 2007). 
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Figure 3. Mutations of CYLD. Misense mutations are indicated by boxes, nonsense mutations by black brackets and frameshift 
mutations by orange bars. Compiled from Blake and Toro, 2009 with additions from Amaro et al., 2009; Kazakov et al., 2009; Nasti et al., 
2009; Wang et al., 2010 and Kazakov et al., 2010. 
 
CYLD has been identified as inactivated by either 
mutation or deletion in multiple myeloma (Annunziata 
et al., 2007; Keats et al., 2007). In this specific case, 
CYLD inactivation has been associated with short-term 
survival (Jenner et al., 2007). 
In the case of melanoma, it has been shown that the 
CYLD promoter region is under negative control by 
snail, a protein which is upregulated in this disease 
(Massoumi et al., 2009). CYLD down-regulation 
results in Bcl3/NF-kappaB activation. 
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